Anticancer compounds polymer activity

New oxidatives applications of PSP have been disclosed recently. PSP [as well as polymer-supported sulfide (PSS) [44] mediated Swern oxidation] can efficiently oxidize secondary amines to their corresponding imines [45]. Various pyrrolo[2,l-c][l,4]benzodiazepines 30 (PBDs), a family of compounds showing anticancer and antibiotic activity, have been cleanly prepared following this method (Scheme... 

In the field of bioresorbable polymers, dendrimers are usually not included. In contrast, polymerosomes, polymeric micelles, and polymeric NPs find a large number of applications as bioresorbable systems, mainly in dmg delivery. It is an extremely vast field of research that covers the development and use of innovative systems for the administration of pharmaceutically active ingredients. In this case there are numerous administration routes for dehvering the active ingredients loaded in these systems, such as oral, transmucosal, pulmonary, and intravenous. The preferable route is oral (noninvasive dehvery), although very often it is not feasible, as with anticancer compounds for which the intravenous route (invasive delivery) is preferred (Fig. 12.1) [1]. 

Various phosphorus compounds can be synthesized by P-H bond addition to unsaturated organic molecules (alkynes, alkenes, dienes, aldehydes and imines). The target products are in demand as biologically active compounds [8-26], useful compounds in nucleic acid chemistry [27-31], versatile reagents in synthesis [32-36] and building blocks in polymer sciences [37-43]. In the area of biologically active compounds antifungal and antibacterial properties of vinyl phospho-nates were considered as well as their anticancer and antiviral activity was evaluated [44 7]. Practical application includes utilization of phosphorus compounds in fuel cell membranes, optical materials and flame retardants [48-55]. 

The polymeric nature may inhibit premature drug deactivation. Thus, cisplatin (structure 19.20), the most widely used anticancer drug, is converted into numerous inactive, but more toxic, platinum-containing compounds before it arrives at the targeted cancer cells. Placement of the active platinum-containing moiety into a polymer (structure 19.21) decreases this tendency to hydrolyze into these unwanted cisplatin compounds because of the greater hydrophobic character of the polymeric drug. 

The use of organotin-containing compounds as potential drugs in the war against cancer has occurred since the early 1970s with some but only mild suc-cess. We more recently began to focus on the anti-cancer activity of organotin polymers that we had made for other purposes and as part of our platinum anticancer effort. Here, we will briefly review these efforts. 

---